A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet^®/Daivobet^®/Taclonex^®) in the treatment of psoriasis vulgaris

Abstract

Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment.